@entity1358 ( @entity1358 ) are capable of tremendous migratory potential to areas of pathology in the central nervous system. When implanted into a diseased or injured nervous system, @entity1358 can travel through great distances to and engraft within areas of discrete as well as @entity66 . Engraftment is often followed by integration into the local neural milieu, accompanied by stable gene expression from the @entity1358 . In addition, the pluripotency of @entity1358 endows them with the capability to replace diseased tissues in an appropriate manner. Recent evidence has also suggested that engrafted exogenous @entity1358 may have effects on the surrounding microenvironment, such as promoting protection and/or regeneration of host neural pathways. These characteristics of @entity1358 would seem to make them ideal agents for the treatment of various central nervous system pathologies, especially @entity1313 . @entity1313 are generally difficult to treat because of the unique location of the lesions. In @entity11 , the extensive infiltrative nature of the @entity5 cells presents a challenge for their effective and total eradication, hence the high rate of treatment failure and disease recurrence. In addition, normal brain structures are distorted and are often destroyed by the growing @entity5 . Even with effective therapy to surgically resect and destroy the neoplastic tissues, the brain is still injured, which often leaves the @entity1 in a debilitated state. The unique ability of @entity1358 to "home in" on @entity5 cells followed by the delivery of a desired gene product makes the NSC a very promising agent in @entity1313 therapy. Cytolytic viruses and genes coding for anti- @entity5 cytokines, pro-drug converting enzymes, and various neurotrophic factors have all been engineered into engraftable @entity1358 for delivery to @entity5 . When they are specially tagged, such injected @entity1358 can be visualized with the use of novel imaging techniques and tracked in vivo within living animals over real time. If the @entity1358 were also capable of participating in the subsequent repair and regeneration of the @entity5 -afflicted brain-at present a potential but as-yet-unproven aspect of this intervention-then its role in abetting anti- @entity5 therapy would be complete. It is important to emphasize, however, that the use of @entity1358 is adjunctive and is not a replacement for other therapies that should be used in parallel.

Neural stem cell biology may be well suited for improving XXXX therapies.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity66 :: ('MESH:D004194', 'Disease') :: ['diffuse abnormalities'] @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumor', 'Brain tumors', 'brain tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'neoplasm'] @entity11 :: ('MESH:D005910', 'Disease') :: ['primary gliomas'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['NSCs', 'Neural stem cells']
@entity1313 :: (MESH:D001932,Disease) :: ['brain tumor']
